Post by shahadat560 on Jan 18, 2024 10:25:18 GMT
The director general of the World Health Organization (WHO), Tedros Adhanom Ghebreyesus , announced this Monday that the organization will temporarily stop clinical trials with hydroxychloroquine in COVID-19 patients, after detecting a higher mortality rate in patients who received that treatment.
The decision, a precautionary measure that could be reviewed, was taken after the publication last Friday in the medical journal The Lancet of a study in which higher mortality rates were reported in patients in whom treatments with hydroxychloroquine had been tested. , commonly used against malaria.
"After reading the publication, we decided in light Country Email List of these doubts to be cautious and temporarily suspend affiliation with this medicine," explained WHO chief scientist Soumya Swaminathan Chief Scientist .
After the pause in the trials, the WHO will continue collecting data to confirm those published by The Lancet and will review the decision in future meetings with medical officials from the countries that carry out the trials sponsored by the organization, under the Solidarity Trial program .
The precautionary measure, which could affect countries like Brazil (who last week had approved the widespread use of hydroxychloroquine in Covid-19 patients) in principle does not apply to chloroquine, of which the previous one is a derivative and which It is also included in WHO clinical trials.
More than 400 hospitals in 35 countries, including Spain, participate in the Solidarity Trials , in which 3,500 patients have been recruited.
Other clinical trials sponsored by the WHO test patients with the antiviral remdesivir (commonly used against Ebola), a combination of lopinavir and ritonavir (commonly used for HIV carriers) and interferon beta, a common treatment against multiple sclerosis.
The president of the United States, Donald Trump , announced last week that he was taking this medication despite not having contracted the virus and the warning from the White House doctor that there were no conclusive results that its use was effective for treat Covid-19, in addition to being a treatment that can cause side effects.
The decision, a precautionary measure that could be reviewed, was taken after the publication last Friday in the medical journal The Lancet of a study in which higher mortality rates were reported in patients in whom treatments with hydroxychloroquine had been tested. , commonly used against malaria.
"After reading the publication, we decided in light Country Email List of these doubts to be cautious and temporarily suspend affiliation with this medicine," explained WHO chief scientist Soumya Swaminathan Chief Scientist .
After the pause in the trials, the WHO will continue collecting data to confirm those published by The Lancet and will review the decision in future meetings with medical officials from the countries that carry out the trials sponsored by the organization, under the Solidarity Trial program .
The precautionary measure, which could affect countries like Brazil (who last week had approved the widespread use of hydroxychloroquine in Covid-19 patients) in principle does not apply to chloroquine, of which the previous one is a derivative and which It is also included in WHO clinical trials.
More than 400 hospitals in 35 countries, including Spain, participate in the Solidarity Trials , in which 3,500 patients have been recruited.
Other clinical trials sponsored by the WHO test patients with the antiviral remdesivir (commonly used against Ebola), a combination of lopinavir and ritonavir (commonly used for HIV carriers) and interferon beta, a common treatment against multiple sclerosis.
The president of the United States, Donald Trump , announced last week that he was taking this medication despite not having contracted the virus and the warning from the White House doctor that there were no conclusive results that its use was effective for treat Covid-19, in addition to being a treatment that can cause side effects.